Residency · Residency · Family Medicine
Breast Health: Evaluation of Breast Complaints and Screening Follow-Up
Overview
Breast complaints are among the most common reasons for primary care visits. Family physicians must skillfully evaluate breast masses, pain, and nipple discharge, interpret screening mammography results using the BI-RADS classification, and guide patients through follow-up of abnormal findings while avoiding both over- and under-investigation.
Breast Anatomy and Physiology
Breast tissue extends from the 2nd to 6th rib and from the sternum to the mid-axillary line. It is composed of 15 to 20 lobes of glandular tissue arranged radially around the nipple, with Cooper ligaments providing structural support. Breast tissue is hormonally responsive, with estrogen and progesterone causing cyclic proliferation and involution. Lymphatic drainage flows primarily to the axillary lymph nodes (approximately 75%), with additional drainage to the internal mammary and supraclavicular nodes.
Clinical Breast Exam (CBE)
Systematic inspection should be performed with the patient's arms at the sides, raised overhead, and pressing hands on hips to contract the pectoralis muscles. The examiner observes for asymmetry, skin dimpling, retraction, erythema, peau d'orange, and nipple inversion. Palpation is performed with the patient supine and the ipsilateral arm above the head, using the pads of three middle fingers in concentric circles or vertical strips. Findings should be documented by clock position, size, shape, consistency, mobility, tenderness, and skin changes. Axillary, supraclavicular, and infraclavicular lymph nodes should be examined.
Evaluation of Breast Masses
History
The history should establish the duration of the mass, any change over time, and its relationship to the menstrual cycle. Associated pain, skin changes, and nipple discharge should be noted. Personal and family history of breast cancer, including first-degree relatives and age at diagnosis, prior breast biopsies, hormone use, and radiation exposure should be assessed. Risk assessment tools such as the Gail model and Tyrer-Cuzick model help quantify individual risk.
Age-Based Approach
In women under 30, ultrasound is the first-line imaging modality because dense breast tissue limits mammographic sensitivity; most masses in this age group are benign, typically fibroadenomas or cysts. For women aged 30 to 39, diagnostic mammogram plus ultrasound is appropriate. For women 40 and older, diagnostic mammogram is the primary study, with ultrasound added as needed.
Characteristics Suggesting Benign vs. Malignant
Features suggesting a benign etiology include a mobile, smooth, well-circumscribed, rubbery mass that is tender, bilateral, and exhibits cyclic changes. Features raising concern for malignancy include a hard, fixed mass with irregular borders that is non-tender, unilateral, and associated with skin changes, axillary lymphadenopathy, or bloody nipple discharge.
Common Benign Conditions
Fibroadenoma is the most common solid mass in women under 30, presenting as a well-circumscribed, mobile, rubbery mass. It is confirmed with ultrasound and observed if under 2 cm with classic features, with biopsy indicated if growing or atypical. Breast cysts are common in perimenopausal women; simple cysts confirmed on ultrasound are benign, and aspiration is offered if symptomatic. No further workup is needed if the aspirated fluid is non-bloody and the mass resolves completely. Fibrocystic changes are the most common cause of breast complaints, presenting with cyclic bilateral tenderness and nodularity, managed with reassurance, supportive bra, evening primrose oil, and NSAIDs. Fat necrosis has a history of trauma or surgery and presents as a firm, irregular mass that can mimic cancer on both exam and imaging, requiring biopsy for confirmation. Phyllodes tumor is characterized by rapid growth, can be benign, borderline, or malignant, and requires surgical excision with wide margins. Mastitis and breast abscess present with erythema, warmth, tenderness, and fever, most commonly in lactating women, treated with antibiotics covering MSSA and MRSA and incision and drainage for abscess. Non-lactational mastitis in older women requires biopsy to exclude inflammatory breast cancer.
Nipple Discharge Evaluation
Physiologic or benign discharge is bilateral, multi-duct, non-spontaneous, and milky, green, or yellow in color, commonly seen with fibrocystic changes, medications, or galactorrhea. Pathologic or concerning discharge is unilateral, single-duct, spontaneous, and bloody or serous. The most common cause of pathologic discharge is intraductal papilloma, which is benign, but ductal carcinoma in situ and invasive cancer must be excluded. The workup for pathologic discharge includes diagnostic mammogram, ultrasound (which may identify an intraductal papilloma or mass), and ductography or MRI if mammogram and ultrasound are negative. Surgical referral for duct excision is warranted if the discharge persists. Galactorrhea presents as milky bilateral discharge unrelated to lactation, and the workup should include prolactin and TSH levels, with evaluation for causative medications such as antipsychotics, metoclopramide, and oral contraceptives.
Breast Cancer Screening
Mammography Guidelines (Varying Recommendations)
The USPSTF 2024 update recommends biennial mammography starting at age 40 through 74. The ACS recommends annual mammography starting at age 45, with the option to start at 40 to 44, and biennial screening at 55 and beyond with the option to continue annually. The ACR recommends annual mammography starting at age 40. All organizations agree on the importance of shared decision-making, especially at the initiation of screening and beyond age 75.
Risk Assessment for Enhanced Screening
Women with a lifetime risk of 20% or above should receive annual breast MRI in addition to mammography. Risk factors warranting enhanced screening include BRCA1 or BRCA2 carrier status, having a first-degree relative with a BRCA mutation, prior chest radiation between ages 10 and 30, and Li-Fraumeni or other hereditary cancer syndromes. The Tyrer-Cuzick (IBIS) model is the most validated tool for determining enhanced screening eligibility.
Supplemental Screening for Dense Breasts
Dense breasts, classified as BI-RADS density C or D, reduce mammographic sensitivity. Supplemental screening options include contrast-enhanced mammography, breast MRI, molecular breast imaging, and whole-breast ultrasound. Many states now mandate dense breast notification, and shared decision-making about supplemental screening is appropriate.
BI-RADS Classification
Categories
| BI-RADS | Assessment | Malignancy Risk | Management |
|---|---|---|---|
| 0 | Incomplete | — | Additional imaging needed |
| 1 | Negative | Essentially 0% | Routine screening |
| 2 | Benign finding | Essentially 0% | Routine screening |
| 3 | Probably benign | <2% | Short-interval follow-up at 6 months |
| 4A | Low suspicion | 2-10% | Biopsy |
| 4B | Moderate suspicion | 10-50% | Biopsy |
| 4C | High suspicion | 50-95% | Biopsy |
| 5 | Highly suggestive of malignancy | >95% | Biopsy |
| 6 | Known malignancy | 100% | Surgical planning |
BI-RADS 0 indicates an incomplete assessment requiring additional imaging such as additional views, ultrasound, or prior films for comparison. BI-RADS 1 is negative, warranting routine screening. BI-RADS 2 identifies a benign finding such as a cyst, calcified fibroadenoma, or lymph node, also warranting routine screening. BI-RADS 3 indicates a probably benign finding with less than 2% malignancy risk, managed with short-interval follow-up imaging at 6 months. BI-RADS 4 is suspicious and requires biopsy, subdivided into 4A (low suspicion, 2 to 10%), 4B (moderate suspicion, 10 to 50%), and 4C (high suspicion, 50 to 95%). BI-RADS 5 is highly suggestive of malignancy with a risk exceeding 95%, and biopsy is required. BI-RADS 6 designates a known biopsy-proven malignancy.
Management by BI-RADS
BI-RADS 0 prompts additional imaging as recommended. BI-RADS 1 and 2 return to the routine screening interval. BI-RADS 3 requires 6-month follow-up imaging, and if stable at 12 to 24 months, the finding is downgraded to BI-RADS 2. BI-RADS 4 and 5 require tissue diagnosis, with core needle biopsy preferred over fine-needle aspiration. Radiologic-pathologic concordance is essential: if the biopsy result does not explain the imaging finding, the case should be discussed at a multidisciplinary conference or the biopsy should be repeated.
Breast Biopsy
Core needle biopsy is the preferred method and is performed with image guidance (ultrasound or stereotactic), providing histologic architecture. Fine-needle aspiration provides cytology only, has a limited role, may miss DCIS, and has a higher false-negative rate. Excisional biopsy is considered when core biopsy is not feasible or results are discordant. Vacuum-assisted biopsy provides a larger tissue sample and is particularly useful for calcifications.
High-Risk Lesions on Biopsy
Atypical ductal hyperplasia warrants excision because upgrade rates to DCIS or cancer at excision reach 15 to 30%. Atypical lobular hyperplasia should be considered for excision, with close surveillance and discussion of chemoprevention. Lobular carcinoma in situ is a marker of increased bilateral breast cancer risk and is managed with surveillance plus chemoprevention using tamoxifen, raloxifene, or an aromatase inhibitor; excision is not required unless the pleomorphic variant is present. Flat epithelial atypia often warrants excision, though upgrade rates vary.
Chemoprevention for High-Risk Women
Chemoprevention should be offered to women with a 5-year breast cancer risk of 3% or above based on the NCI Breast Cancer Risk Assessment Tool. Tamoxifen is available for pre- and postmenopausal women and reduces invasive breast cancer risk by approximately 50%, with risks including VTE and endometrial cancer. Raloxifene is available for postmenopausal women only and achieves a similar risk reduction with lower VTE and endometrial risk compared to tamoxifen. Aromatase inhibitors such as exemestane and anastrozole are for postmenopausal women and reduce risk by approximately 65%, with musculoskeletal side effects as the main limitation.
<image>The BI-RADS classification system displayed as a visual reference chart showing categories 0-6 with representative mammographic appearances, malignancy risk percentages, and recommended management actions for each category, including follow-up intervals and biopsy decision points.</image>
<image>A clinical algorithm for evaluating a palpable breast mass showing age-stratified imaging approach (ultrasound first for age <30, mammogram plus ultrasound for age 30+), assessment of solid vs. cystic on ultrasound, and management pathways including observation, aspiration, core needle biopsy, and surgical referral based on imaging and clinical features.</image>
<image>A diagram of nipple discharge evaluation showing the differentiation between physiologic (bilateral, multi-duct, non-spontaneous) and pathologic (unilateral, single-duct, spontaneous, bloody) discharge, with appropriate workup steps including mammography, ultrasound, ductography, and surgical referral for each pathway.</image>
Clinical Pearls
A palpable mass that persists through a menstrual cycle requires imaging regardless of patient age and should not be dismissed as fibrocystic changes without proper evaluation. Core needle biopsy is preferred over fine-needle aspiration for most breast lesions because it provides histologic architecture and can distinguish invasive from in situ carcinoma. Radiologic-pathologic concordance is essential: if the biopsy result does not adequately explain the imaging finding, the case must be discussed at a multidisciplinary conference or re-biopsied. BI-RADS 3 lesions have less than 2% malignancy risk but require 6-month follow-up, and patient compliance with short-interval follow-up must be ensured. Non-lactational mastitis in a postmenopausal woman should raise suspicion for inflammatory breast cancer, and biopsy is warranted if the condition does not respond to antibiotics. Dense breast tissue significantly reduces mammographic sensitivity, and supplemental screening options should be discussed based on individual risk assessment. Galactorrhea workup should include prolactin and TSH, as drug-induced hyperprolactinemia is the most common cause. Breast cancer chemoprevention is underutilized in primary care and should be discussed with eligible high-risk patients using shared decision-making.
References
- USPSTF Breast Cancer Screening Recommendations. JAMA. 2024
- ACR Practice Guideline for Breast Cancer Screening. J Am Coll Radiol. 2023
- Sickles EA et al. ACR BI-RADS Atlas, 5th Edition. American College of Radiology. 2013
- ACOG Practice Bulletin: Breast Cancer Risk Assessment and Screening. Obstet Gynecol. 2017
- Nelson HD et al. Screening for Breast Cancer: Systematic Review. Ann Intern Med. 2016
